Asensus Surgical, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2023-11-16: Form 8-K; Period of report 2023-11-14; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2023-09-19: Form 8-K; Period of report 2023-09-19; Description 8.01 Other Events; Details 8.01.
- 2023-08-11: Form 8-K; Period of report 2023-08-10; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2023-07-28: Form 8-K; Period of report 2023-07-27; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2023-11-16 | 8-K | 2023-11-14 | 2.02 Results of Operations and Financial Condition | 2.02 On November 14, 2023, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the third quarter ended September 30, 2023. | asxc20231114_8k.htm |
| 2023-09-19 | 8-K | 2023-09-19 | 8.01 Other Events | 8.01 On July 14, 2023, Asensus Surgical, Inc., a Delaware corporation (the “Company”) announced that a leading United States-based hospital had entered into a lease of the Company’s Senhance® Surgery System for use in pediatric surgery. | asxc20230918_8k.htm |
| 2023-08-11 | 8-K | 2023-08-10 | 2.02 Results of Operations and Financial Condition | 2.02 On August 10, 2023, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2023. | asxc20230810_8k.htm |
| 2023-07-28 | 8-K | 2023-07-27 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On July 27, 2023, Asensus Surgical, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the certain purchasers signatory thereto (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a registered direct offering (the “Offering”) (i) 23,809,524 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) common warrants to purchase up to an aggregate of 23,809,524 shares of Common Stock (the “Warrants”). 8.01 On July 27, 2023, the Company issued a press release announcing pricing of the Offering and the entry into the Purchase Agreement. | asxc20230724_8k.htm |
| 2023-06-30 | 8-K | 2023-06-30 | 8.01 Other Events | 8.01 On February 16, 2023, Asensus Surgical, Inc. (the “Company”) announced that it had entered into a Memorandum of Understanding (“MoU”) with KARL STORZ VentureONE Pte. | asxc20230629_8k.htm |
| 2023-06-06 | 8-K | 2023-06-06 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 5.02 On June 6, 2023, at the 2023 Annual Meeting of Stockholders (the “Annual Meeting”), the stockholders of Asensus Surgical, Inc. (the “Company”) voted to approve, among other things, the Company’s Amended and Restated Incentive Compensation Plan (the “Plan”) to increase the number of shares reserved for issuance under the Plan by 22,000,000 shares. 5.07 On June 6, 2023, the Company held the Annual Meeting. | asxc20230601_8k.htm |
| 2023-06-05 | 8-K | 2023-06-05 | 7.01 Regulation FD Disclosure | 7.01 On June 5, 2023, Asensus Surgical, Inc. (the “Company”) updated its corporate presentation. | asxc20230604_8k.htm |
| 2023-05-15 | 8-K | 2023-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2023, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2023. | asxc20230511_8k.htm |
| 2023-03-02 | 8-K | 2023-03-02 | 2.02 Results of Operations and Financial Condition | 2.02 On March 2, 2023, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2022. | asxc20230302_8k.htm |
| 2023-02-21 | 8-K | 2023-02-21 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On February 21, 2023, Asensus Surgical, Inc. (the “Company”) is hosting an Investor Day to provide a corporate update to investors. 8.01 The Company issued a press release just prior to hosting its Investor Day on February 21, 2023. | asxc20230216_8k.htm |
| 2023-01-12 | 8-K | 2023-01-09 | 8.01 Other Events | 8.01 On January 9, 2023, Asensus Surgical, Inc., a Delaware corporation (the “Company”), issued a press release announcing an update with preliminary financial results for the fourth quarter and full year ended December 31, 2022. | asxc20230112_8k.htm |